Banyu Submits NDA For Skin Cancer Drug Vorinostat
This article was originally published in PharmAsia News
Executive SummaryMerck subsidiary Banyu Pharmaceutical submitted a new drug approval application in Japan for skin cancer drug vorinostat
You may also be interested in...
All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.